Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence
Tóm tắt
Chronic spontaneous urticaria (CSU) is defined as the spontaneous development of itchy hives and/or angioedema due to known or unknown causes that last for at least 6 weeks. At any given time, CSU is believed to affect 0.5–1% of the global population. Omalizumab (a recombinant, humanized anti-immunoglobulin-E antibody) is the only approved treatment for antihistamine refractory CSU. However, ~ 30% of patients remain symptomatic at licensed doses of omalizumab 150 mg and 300 mg, even after a treatment period of over 6 months. In the recent years, there have been several studies on updosing of the drug, suggesting that the individualized approach for urticaria treatment with omalizumab is useful. In this article, we provide an overview of these studies and the real-world data on omalizumab updosing as it became necessary to obtain complete CSU symptom control in a proportion of patients. Published observational studies (from June 2003 to October 2019) on the updosing of omalizumab in CSU were identified using PubMed and Ovid databases. Reports mainly show that updosing/dose adjustment evaluated with the assessment of disease activity (Urticaria Activity Score) and control (Urticaria Control Test) achieves better clinical response to omalizumab with a good safety profile in a pool of patients with CSU. These real-world data will provide an overview of updosing of omalizumab in CSU and aid in setting informed clinical practice treatment expectations.
Tài liệu tham khảo
Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, Bernstein JA, Bindslev-Jensen C, Brzoza Z, Buense Bedrikow R, Canonica GW, Church MK, Craig T, Danilycheva IV, Dressler C, Ensina LF, Giménez-Arnau A, Godse K, Gonçalo M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Katelaris CH, Kocatürk E, Kulthanan K, Larenas-Linnemann D, Leslie TA, Magerl M, Mathelier-Fusade P, Meshkova RY, Metz M, Nast A, Nettis E, Oude-Elberink H, Rosumeck S, Saini SS, Sánchez-Borges M, Schmid-Grendelmeier P, Staubach P, Sussman G, Toubi E, Vena GA, Vestergaard C, Wedi B, Werner RN, Zhao Z, Maurer M, Endorsed by the following societies: AAAAI, AAD, AAIITO, ACAAI, AEDV, APAAACI, ASBAI, ASCIA, BAD, BSACI, CDA, CMICA, CSACI, DDG, DDS, DGAKI, DSA, DST, EAACI, EIAS, EDF, EMBRN, ESCD, GA²LEN, IAACI, IADVL, JDA, NVvA, MSAI, ÖGDV, PSA, RAACI, SBD, SFD, SGAI, SGDV, SIAAIC, SIDeMaST, SPDV, TSD, UNBB, UNEV and WAO (2018) The eaaci/ga(2)len/edf/wao guideline for the definition, classification, diagnosis and management of urticaria. Allergy 73(7):1393–1414. https://doi.org/10.1111/all.13397
Gimenez Arnau AM, Valero Santiago A, Bartra Tomas J et al (2019) Therapeutic strategy according to differences in response to omalizumab in patients with chronic spontaneous urticaria. J Investig Allergol Clin Immunol 29(5):338–348. https://doi.org/10.18176/jiaci.0323
Westby EP, Lynde C, Sussman G (2018) Chronic urticaria: following practice guidelines. Skin Therapy Lett 23(3):1–4
Fricke J, Avila G, Keller T et al (2019) Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 75:423–432. https://doi.org/10.1111/all.14037
Greaves M (2000) Chronic urticaria. J Allergy Clin Immunol 105(4):664–672. https://doi.org/10.1067/mai.2000.105706
Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, Grattan CEH, Kapp A, Maurer M, Merk HF, Rogala B, Saini S, Sánchez-Borges M, Schmid-Grendelmeier P, Schünemann H, Staubach P, Vena GA, Wedi B (2009) Eaaci/ga(2)len/edf/wao guideline: management of urticaria. Allergy 64(10):1427–1443. https://doi.org/10.1111/j.1398-9995.2009.02178.x
Guo C, Saltoun C (2019) Urticaria and angioedema. Allergy Asthma Proc 40(6):437–440. https://doi.org/10.2500/aap.2019.40.4266
Kanani A, Betschel SD, Warrington R (2018) Urticaria and angioedema. Allergy Asthma Clin Immunol 14(Suppl 2):59. https://doi.org/10.1186/s13223-018-0288-z
Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, Canonica GW, Church MK, Godse KV, Grattan CEH, Greaves MW, Hide M, Kalogeromitros D, Kaplan AP, Saini SS, Zhu XJ, Zuberbier T (2011) Unmet clinical needs in chronic spontaneous urticaria. A ga(2)len task force report. Allergy 66(3):317–330. https://doi.org/10.1111/j.1398-9995.2010.02496.x
Sussman G, Abuzakouk M, Berard F et al (2018) Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: analyses from assure-csu. Allergy 73(8):1724–1734. https://doi.org/10.1111/all.13430
Church MK, Kolkhir P, Metz M, Maurer M (2018) The role and relevance of mast cells in urticaria. Immunol Rev 282(1):232–247. https://doi.org/10.1111/imr.12632
Maurer M, Altrichter S, Schmetzer O, Scheffel J, Church MK, Metz M (2018) Immunoglobulin e-mediated autoimmunity. Front Immunol 9:689. https://doi.org/10.3389/fimmu.2018.00689
Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, Veith J, Kamath N, Staubach P, Jakob T, Stirling RG, Kuna P, Berger W, Maurer M, Rosén K (2013) Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 132(1):101–109. https://doi.org/10.1016/j.jaci.2013.05.013
Maurer M, Rosen K, Hsieh HJ et al (2013) Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 368(10):924–935. https://doi.org/10.1056/NEJMoa1215372
Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bülbül Baskan E, Bradley MS, Canvin J, Rahmaoui A, Georgiou P, Alpan O, Spector S, Rosén K (2015) Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on h1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 135(1):67–75. https://doi.org/10.1038/jid.2014.306
Labrador-Horrillo M, Valero A, Velasco M, Jáuregui I, Sastre J, Bartra J, Silvestre JF, Ortiz de Frutos J, Gimenez-Arnau A, Ferrer M (2013) Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice. Expert Opin Biol Ther 13(9):1225–1228. https://doi.org/10.1517/14712598.2013.822484
Metz M, Ohanyan T, Church MK, Maurer M (2014) Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci 73(1):57–62. https://doi.org/10.1016/j.jdermsci.2013.08.011
Rottem M, Segal R, Kivity S, Shamshines L, Graif Y, Shalit M, Kessel A, Panasoff J, Cohen S, Toubi E, Agmon-Levin N (2014) Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience. Isr Med Assoc J 16(8):487–490
Sussman G, Hebert J, Barron C et al (2014) Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol 112(2):170–174. https://doi.org/10.1016/j.anai.2013.12.005
Thomsen SF, Pritzier EC, Anderson CD, Vaugelade-Baust N, Dodge R, Dahlborn AK, Vestergaard C (2017) Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre aware study. J Eur Acad Dermatol Venereol 31(6):1048–1055. https://doi.org/10.1111/jdv.14210
Metz M, Staubach P, Bauer A, Brehler R, Gericke J, Kangas M, Ashton-Chess J, Jarvis P, Georgiou P, Canvin J, Hillenbrand R, Erpenbeck VJ, Maurer M (2017) Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of Fc epsilon RI-positive cells in the skin. Theranostics 7(5):1266–1276. https://doi.org/10.7150/thno.18304
Kolkhir P, Church MK, Weller K et al (2017) Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol 139(6):1772–1781.e1771. https://doi.org/10.1016/j.jaci.2016.08.050
Kaplan AP, Gimenez-Arnau AM, Saini SS (2017) Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy 72(4):519–533. https://doi.org/10.1111/all.13083
Ferrer M, Boccon-Gibod I, Goncalo M et al (2017) Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria. Eur J Dermatol 27(5):455–463. https://doi.org/10.1684/ejd.2017.3085
Weller K, Church MK, Metz M et al (2019) The response to treatment in chronic spontaneous urticaria depends on how it is measured. J Allergy Clin Immunol Pract 7(6):2055–2056.e2054. https://doi.org/10.1016/j.jaip.2019.01.048
FDA U (2014) Xolair® (omalizumab) for injection, for subcutaneous use https://www.accessdatafdagov/drugsatfda_docs/label/2014/103976s5211lblpdf
Fiorino I, Loconte F, Rucco AS, Nico A, Vacca M, Damiani E, Nettis E, Caiaffa MF, Macchia L (2014) Long-term treatment of refractory severe chronic urticaria by omalizumab: analysis of two cases. Postepy Dermatol Alergol 31(5):332–334. https://doi.org/10.5114/pdia.2014.44023
Larenas-Linnemann DES, Parisi CAS, Ritchie C, Cardona-Villa R, Cherrez-Ojeda I, Cherrez A, Ensina LF, Garcia E, Medina IV, Rodríguez-González M, Caraballo JMS (2018) Update on omalizumab for urticaria: what’s new in the literature from mechanisms to clinic. Curr Allergy Asthma Rep 18(5):33. https://doi.org/10.1007/s11882-018-0787-5
Turk M, Kocaturk E, Cure K et al (2018) Two-week intervals during omalizumab treatment may provide better symptom control in selected patients with chronic urticaria. J Allergy Clin Immunol Pract 6(4):1389–1390. https://doi.org/10.1016/j.jaip.2018.01.027
Spertino J, Curto Barredo L, Rozas Munoz E et al (2018) Algorithm for treatment of chronic spontaneous urticaria with omalizumab. Actas Dermosifiliogr 109(9):771–776. https://doi.org/10.1016/j.ad.2018.07.005
Uysal P, Eller E, Mortz CG et al (2014) An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized. J Allergy Clin Immunol 133(3):914–915.e912. https://doi.org/10.1016/j.jaci.2013.10.015
Boushey HA Jr (2001) Experiences with monoclonal antibody therapy for allergic asthma. J Allergy Clin Immunol 108(2 Suppl):S77–S83
Bracken SJ, Abraham S, MacLeod AS (2019) Autoimmune theories of chronic spontaneous urticaria. Front Immunol 10:627. https://doi.org/10.3389/fimmu.2019.00627
Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, Deniz Y (2003) Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 19(6):491–498. https://doi.org/10.1185/030079903125002171
Boyce JA (2006) Successful treatment of cold-induced urticaria/anaphylaxis with anti-ige. J Allergy Clin Immunol 117(6):1415–1418. https://doi.org/10.1016/j.jaci.2006.04.003
Gober LM, Sterba PM, Eckman JA et al (2008) Effect of anti-ige (omalizumab) in chronic idiopathic urticaria (ciu) patients. J Allergy Clin Immunol 121(2):S147. https://doi.org/10.1016/j.jaci.2007.12.1121
Maurer M, Altrichter S, Bieber T et al (2011) Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit ige against thyroperoxidase. J Allergy Clin Immunol 128(1):202–209.e205. https://doi.org/10.1016/j.jaci.2011.04.038
Kaplan AP (2018) Diagnosis, pathogenesis, and treatment of chronic spontaneous urticaria. Allergy Asthma Proc 39(3):184–190. https://doi.org/10.2500/aap.2018.39.4121
Saini S, Rosen KE, Hsieh HJ et al (2011) A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with h1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 128(3):567–573.e561. https://doi.org/10.1016/j.jaci.2011.06.010
Zhao ZT, Ji CM, Yu WJ et al (2016) Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol 137(6):1742–1750.e1744. https://doi.org/10.1016/j.jaci.2015.12.1342
Bernstein JA, Kavati A, Tharp MD, Ortiz B, MacDonald K, Denhaerynck K, Abraham I (2018) Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ‘real-world’ evidence. Expert Opin Biol Ther 18(4):425–448. https://doi.org/10.1080/14712598.2018.1438406
Cordeiro Moreira AS, Rosmaninho Lopes de Soares ESMI, Pereira Guilherme MA et al (2016) Use of omalizumab in the treatment of chronic urticaria. Eur Ann Allergy Clin Immunol 48(6):242–246
Romano C, Sellitto A, De Fanis U et al (2015) Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience. Clin Drug Investig 35(3):159–168. https://doi.org/10.1007/s40261-015-0267-9
Seth S, Khan DA (2017) The comparative safety of multiple alternative agents in refractory chronic urticaria patients. J Allergy Clin Immunol Pract 5(1):165–170.e162. https://doi.org/10.1016/j.jaip.2016.08.010
Kavati A, Zhdanava M, Ortiz B, LeCocq J, Schiffman B, Pilon D, Ching Cheung H, Lefebvre P, Stone BD (2019) Long-term omalizumab outcomes in chronic idiopathic urticaria: a real-world study. Allergy Asthma Proc 40(5):321–328. https://doi.org/10.2500/aap.2019.40.4236
Tharp MD, Bernstein JA, Kavati A, Ortiz B, MacDonald K, Denhaerynck K, Abraham I, Lee CS (2019) Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of “real-world” evidence. JAMA Dermatol 155(1):29–38. https://doi.org/10.1001/jamadermatol.2018.3447
Aghdam M, van den Broek F, Rijken F et al (2019) High-dose omalizumab use in patients with chronic spontaneous urticaria. J Allergy Clin Immunol Pract 8:1426–1427.e1. https://doi.org/10.1016/j.jaip.2019.10.018
Barron C, Saperia C, Kobric D, Sussman GL (2017) Chronic spontaneous urticaria; centres’ of excellence. J Allergy Clin Immunol 139(2):AB247. https://doi.org/10.1016/j.jaci.2016.12.796
Eaaci/escd skin allergy meeting 2017 (sam 2017) (2017) Clin Transl Allergy 7(4):47. https://doi.org/10.1186/s13601-017-0184-5
Vadasz Z, Tal Y, Rotem M, Shichter-Confino V, Mahlab-Guri K, Graif Y, Kessel A, Agmon-Levin N, Maoz-Segal R, Kivity S, Benor S, Lachover-Roth I, Zeldin Y, Stein M, Toker O, Hassoun G, Bezalel-Rosenberg S, Toubi E, Asher I, Sthoeger Z, Israeli Forum for investigating and treating Chronic Spontaneous Urticaria (CSU) (2017) Omalizumab for severe chronic spontaneous urticaria: real-life experiences of 280 patients. J Allergy Clin Immunol Pract 5(6):1743–1745. https://doi.org/10.1016/j.jaip.2017.08.035
Kocaturk E, Deza G, Kiziltac K et al (2018) Omalizumab updosing for better disease control in chronic spontaneous urticaria patients. Int Arch Allergy Immunol 177(4):360–364. https://doi.org/10.1159/000491530
Curto-Barredo L, Spertino J, Figueras-Nart I, Expósito-Serrano V, Guilabert A, Melé-Ninot G, Cubiró X, Bonfill-Ortí M, Garcias-Ladaria J, Villar M, García-Navarro X, Bielsa-Marsol I, Vilavella M, Aparicio G, Baliu-Piqué C, Álvarez A, Lamas-Domenech N, Duran-Jordà X, Serra-Baldrich E, Giménez-Arnau A (2018) Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria. Br J Dermatol 179:210–212. https://doi.org/10.1111/bjd.16379
Salman A, Comert E (2019) The real-life effectiveness and safety of omalizumab updosing in patients with chronic spontaneous urticaria. J Cutan Med Surg 23(5):496–500. https://doi.org/10.1177/1203475419847956
Milgrom H, Fowler-Taylor A, Vidaurre CF, Jayawardene S (2011) Safety and tolerability of omalizumab in children with allergic (ige-mediated) asthma. Curr Med Res Opin 27(1):163–169. https://doi.org/10.1185/03007995.2010.539502
Normansell R, Walker S, Milan SJ et al. (2014) Omalizumab for asthma in adults and children. Cochrane Database Syst Rev (1):Cd003559. https://doi.org/10.1002/14651858.CD003559.pub4